KalVista Pharmaceuticals Crecimiento futuro

Future controles de criterios 5/6

Se prevé un crecimiento anual de los beneficios y los ingresos de KalVista Pharmaceuticals de 54.6% y 45.6% respectivamente, mientras que el BPA crecerá en un 57.3% al año.

Información clave

60.3%

Tasa de crecimiento de los beneficios

62.6%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	28.4%
Tasa de crecimiento de los ingresos	53.2%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Good
Última actualización	06 Sep 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Is KalVista Pharmaceuticals (NASDAQ:KALV) In A Good Position To Deliver On Growth Plans?

Sep 12

KalVista Pharmaceuticals: Looking To Be A Major Player In HAE

Sep 05

Bullish On KalVista Pharmaceuticals: Sebetralstat Nears Approval, Aiming For 2025 Launch

Jun 24

KalVista: Positive Results From Phase 3 Trial Pave The Way For Commercialization (Downgrade)

Feb 14

We're Keeping An Eye On KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Rate

Jan 30

We're Keeping An Eye On KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Rate

Oct 04

We Think KalVista Pharmaceuticals (NASDAQ:KALV) Needs To Drive Business Growth Carefully

May 02

KalVista: Another Setback But The Key Value Driver Is Still In Place

Oct 14

Here's Why We're Watching KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Situation

Sep 24

Is KalVista Pharmaceuticals (NASDAQ:KALV) In A Good Position To Invest In Growth?

May 18

Companies Like KalVista Pharmaceuticals (NASDAQ:KALV) Are In A Position To Invest In Growth

Feb 02

We Discuss Why KalVista Pharmaceuticals, Inc.'s (NASDAQ:KALV) CEO Compensation May Be Closely Reviewed

Sep 24

We're Hopeful That KalVista Pharmaceuticals (NASDAQ:KALV) Will Use Its Cash Wisely

Jul 02

KalVista Pharma's oral KVD900 shows rapid improvement in HAE attacks in mid-stage study

Jun 07

Previsiones de crecimiento de beneficios e ingresos

NasdaqGM:KALV - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
4/30/2027	170	-12	-55	66	4
4/30/2026	87	-103	-139	-49	6
4/30/2025	7	-167	-182	-158	6
7/31/2024	N/A	-142	-103	-103	N/A
4/30/2024	N/A	-127	-90	-89	N/A
1/31/2024	N/A	-108	-97	-97	N/A
10/31/2023	N/A	-101	-79	-78	N/A
7/31/2023	N/A	-95	-80	-79	N/A
4/30/2023	N/A	-93	-76	-75	N/A
1/31/2023	N/A	-91	-81	-79	N/A
10/31/2022	N/A	-92	-86	-84	N/A
7/31/2022	N/A	-89	-85	-83	N/A
4/30/2022	N/A	-82	-79	-78	N/A
1/31/2022	N/A	-73	-63	-62	N/A
10/31/2021	N/A	-61	-57	-56	N/A
7/31/2021	N/A	-52	-45	-44	N/A
4/30/2021	N/A	-46	-30	-30	N/A
1/31/2021	4	-38	-32	-32	N/A
10/31/2020	5	-37	-37	-37	N/A
7/31/2020	9	-33	-37	-37	N/A
4/30/2020	13	-29	-45	-45	N/A
1/31/2020	12	-31	-43	-43	N/A
10/31/2019	14	-26	-41	-40	N/A
7/31/2019	16	-23	-42	-41	N/A
4/30/2019	16	-21	-37	-36	N/A
1/31/2019	18	-13	-34	-32	N/A
10/31/2018	16	-14	5	7	N/A
7/31/2018	12	-16	7	9	N/A
4/30/2018	8	-16	N/A	11	N/A
1/31/2018	4	-19	N/A	14	N/A
10/31/2017	2	-22	N/A	-26	N/A
7/31/2017	1	-21	N/A	-23	N/A
4/30/2017	2	-21	N/A	-24	N/A
1/31/2017	2	-23	N/A	-23	N/A
10/31/2016	2	-18	N/A	-15	N/A
7/31/2016	2	-18	N/A	-15	N/A
4/30/2016	2	-15	N/A	-13	N/A
4/30/2015	2	-9	N/A	-6	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que KALV sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2.5%).

Beneficios vs. Mercado: Se prevé que KALV sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que KALV sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (45.6% al año) de KALV crezcan más rápidamente que los del mercado US (8.8% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (45.6% al año) de KALV crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de KALV se prevé que sea elevada dentro de 3 años.

KalVista Pharmaceuticals Crecimiento futuro

Future controles de criterios 5/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Forecast to breakeven in 2027

Price target increased by 7.6% to US$20.80

Consensus revenue estimates fall by 58%

Price target decreased to US$21.83

Price target decreased to US$32.83

No longer forecast to breakeven

Recent updates

Is KalVista Pharmaceuticals (NASDAQ:KALV) In A Good Position To Deliver On Growth Plans?

KalVista Pharmaceuticals: Looking To Be A Major Player In HAE

Kalvista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary Angioedema

KalVista Pharmaceuticals, Inc., Annual General Meeting, Oct 03, 2024

KalVista Pharmaceuticals, Inc. Announces Validation of Marketing Authorization Application by the European Medicines Agency for Sebetralstat for Hereditary Angioedema

KalVista Pharmaceuticals, Inc. Initiates KONFident-KID Trial for On-Demand Treatment of Hereditary Angioedema Attacks with Sebetralstat in Children Aged 2 to 11

Bullish On KalVista Pharmaceuticals: Sebetralstat Nears Approval, Aiming For 2025 Launch

KalVista Pharmaceuticals, Inc. Submits New Drug Application to FDA for Sebetralstat as First Oral On-Demand Treatment for Hereditary Angioedema

KalVista Pharmaceuticals, Inc. Presents Data At Eastern Allergy Conference 2024 and the Japanese Dermatological Association 2024

Kalvista Pharmaceuticals Presents Data on Persisting Unmet Needs in Hereditary Angioedema At the European Academy of Allergy and Clinical Immunology (Eaaci) Congress 2024

Kalvista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating Its Potential to Transform the Treatment Landscape for People with Hereditary Angioedema

CEO & Director exercised options and sold US$258k worth of stock

Forecast to breakeven in 2027

Kalvista Pharmaceuticals, Inc. Appoints William C. Fairey to the Board of Directors

KalVista Pharmaceuticals, Inc. to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas

KalVista Pharmaceuticals, Inc. Announces Board Changes

New minor risk - Share price stability

CEO & Director exercised options and sold US$351k worth of stock

KalVista Pharmaceuticals, Inc. Receives UK Innovation Passport for Sebetralstat from UK Medicines and Healthcare Products Regulatory Agency

KalVista Pharmaceuticals, Inc. Receives UK Innovation Passport for Sebetralstat from UK Medicines and Healthcare Products Regulatory Agency

New minor risk - Shareholder dilution

CEO & Director recently sold US$876k worth of stock

KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

KalVista Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.

KalVista Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $160.125 million.

KalVista: Positive Results From Phase 3 Trial Pave The Way For Commercialization (Downgrade)

Kalvista Pharmaceuticals, Inc. Reports Phase 3 Konfident Trial Meets All Endpoints for Sebetralstat as First Oral On-Demand Therapy for Hereditary Angioedema

We're Keeping An Eye On KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Rate

Chief Scientific Officer notifies of intention to sell stock

Chief Scientific Officer notifies of intention to sell stock

Chief Scientific Officer notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

New major risk - Financial position

CEO & Director exercised options and sold US$122k worth of stock

Price target increased by 7.6% to US$20.80

Kalvista Pharmaceuticals Announces Phase 3 Konfident Trial Milestone Achieved

KalVista Pharmaceuticals to Present Data at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology

We're Keeping An Eye On KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Rate

Independent Director notifies of intention to sell stock

CEO & Director exercised options and sold US$160k worth of stock

KalVista Pharmaceuticals, Inc., Annual General Meeting, Sep 26, 2023

KalVista Pharmaceuticals, Inc. Appoints Nicole Sweeny as Chief Commercial Officer

Consensus revenue estimates fall by 58%

KalVista Pharmaceuticals, Inc. Presents New Data at 2023 Meeting of the European Academy of Allergy and Clinical Immunology

CEO & Director exercised options and sold US$57k worth of stock

KalVista Pharmaceuticals, Inc. Presents Data At 13Th C1-Inhibitor Deficiency & Angioedema Workshop

We Think KalVista Pharmaceuticals (NASDAQ:KALV) Needs To Drive Business Growth Carefully

KalVista Pharmaceuticals, Inc. Provides Progress Updates on Sebetralstat Development

Kalvista Pharmaceuticals Announces Publication of Sebetralstat Phase 2 Data in the Lancet

Kalvista Pharmaceuticals Announces Benjamin L. Palleiko Promoted to President

Price target decreased to US$21.83

KalVista Pharmaceuticals Presents Patient-Focused Data at American College of Allergy, Asthma & Immunology (ACAAI) 2022 Meeting

Kalvista Pharmaceuticals Announces Positive Phase 1 Data for Orally Disintegrating Tablet Formulation of Sebetralstat for Use in Hereditary Angioedema

KalVista Pharmaceuticals, Inc. Announces Management Changes

KalVista: Another Setback But The Key Value Driver Is Still In Place

KalVista Pharmaceuticals, Inc. Presents New Patient-Centric Data at 2022 HAEi Global Leadership Workshop

KalVista Pharmaceuticals Announces Termination of KVD824 Phase 2 KOMPLETE Trial for Prophylactic Treatment of Hereditary Angioedema

Price target decreased to US$32.83

Here's Why We're Watching KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Situation

CEO & Director notifies of intention to sell stock

KalVista Pharmaceticals GAAP EPS of -$0.94

Kalvista Pharmaceuticals, Inc. Announces Initiation of KONFIDENT-S Open Label Extension Study for Sebetralstat in Hereditary Angioedema

KalVista Pharmaceuticals, Inc., Annual General Meeting, Oct 13, 2022

KalVista reaches five-month high as rival tumbles on hereditary angioedema

No longer forecast to breakeven

KalVista Pharmaceticals GAAP EPS of -$0.98 beats by $0.11

Price target decreased to US$41.67

KalVista Pharmaceuticals, Inc. Announces Board Changes